APOH
Beta-2-glycoprotein 1
Protein Summary
Binds to various kinds of negatively charged substances such as heparin, phospholipids, and dextran sulfate. May prevent activation of the intrinsic blood coagulation cascade by binding to phospholipids on the surface of damaged cells. Apolipoprotein H has been implicated in a variety of physiologic pathways including lipoprotein metabolism, coagulation, and the production of antiphospholipid autoantibodies. APOH may be a required cofactor for anionic phospholipid binding by the antiphospholipid autoantibodies found in sera of many patients with lupus and primary antiphospholipid syndrome, but it does not seem to be required for the reactivity of antiphospholipid autoantibodies associated with infections. [provided by RefSeq, Jul 2008]
- ENST00000205948
- ENSP00000205948
- ENSG00000091583
- B2G1
- BG
- B2G1
- B2GP1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological term | 0.94 | ||
biological process | 0.8 | ||
disease | 0.69 | ||
molecular function | 0.63 | ||
cell line | 0.59 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 2173.66 (req: < 5)
Gene RIFs: 182 (req: <= 3)
Antibodies: 502 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 2173.66 (req: >= 5)
Gene RIFs: 182 (req: > 3)
Antibodies: 502 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 20
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0